PDFs by language
Our 24/7 cancer helpline provides support for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
At our National Cancer Information Center trained Cancer Information Specialists can answer questions 24 hours a day, every day of the year to empower you with accurate, up-to-date information to help you make educated health decisions. We connect patients, caregivers, and family members with valuable services and resources.
Or ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Grantee: Eva Hernando, PhD
Institution: New York University School of Medicine in New York City
Area of Study: Cell Structure and Metastasis
Grant Term: 1/1/20 to 12/31/22
The Challenge: In some cases, melanoma can spread, or metastasize, to the brain. Researchers don’t fully understand how melanoma cells travel to and grow in the brain to form new tumors. Currently, there are few treatments available for brain metastasis.
The Research: While studying a melanoma tumor that had metastasized and formed in the brain, Eva Hernando, PhD, and her team discovered something unexpected. They found unusually high levels of proteins that are related to Alzheimer’s disease, including one called amyloid processing protein (APP).
Normally, APP plays a role in nerve function of many tissues and organs throughout the body. But certain changes that can happen in APP have been linked to Alzheimer’s disease. Hernando’s team found that APP is also essential for melanoma cells to adapt to the brain.
Hernando is studying:
The Goal and Long-term Possibilities: As soon as Hernando’s team finishes their mice studies, they hope to rapidly start testing it in people who have melanoma brain metastases, since the substances involved have already been through safety testing in humans. If this work is successful, it may change how brain metastases are treated and may improve the outcomes of people with certain types of metastatic tumors.